@Article{,
AUTHOR = {Shridhar C. Ghagane, Shadab Rangrez, R.B. Nerli, Madhukar L. Thakur, Leonard G. Gomella},
TITLE = {Use of TP4303 to identify prostate cancer cells in voided urine samples},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {3},
PAGES = {11892--11896},
URL = {http://www.techscience.com/CJU/v31n3/59587},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Prostate cancer is the second most
common malignancy in men worldwide. Genomic VPAC
receptors are expressed on malignant prostate cancer cells
and can be targeted and imaged optically by a peptide
labeled fluorophore. The objective of our study was to
assess the feasibility of detecting cancer of the prostate
using a voided urine sample.<br/>
<b>Materials and methods:</b> Patients ≥ 40 years old, with
lower urinary tract symptoms and serum PSA > 4 ng/
mL formed the study group. The first 50 mL of voided
urine sample was collected and processed. The cells that
were shed in the voided urine were fixed and stained
with a peptide TP4303 and incubated. The slide was
then stained with DAPI which binds with the DNA in the nucleus. All patients underwent a standard 12-core
TRUS-guided prostate biopsy.<br/>
<b>Results:</b> A total of 318 patients were included in the
study, of these 158 were histologically confirmed cancers.
Voided urine samples were positive for VPAC receptors
in 154 (97.46%) of these. The remaining 160 patients
had no cancer on the HPR examination and none of these
patients were positive for VPAC receptors.<br/>
<b>Conclusions:</b> This study validates our belief that patients
with prostate cancer shed malignant cells in the urine that
can be identified by targeting the VPAC receptors. If these
results are further validated by multicentric studies, then
this could form the basis for indications for a preliminary
prostate biopsy in patients with elevated serum PSA
but normal digital examination or in patients needing a
repeat biopsy.},
DOI = {}
}